Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID06642428

Effect of Vitamin D Supplementation on Efficacy and Side Effects of Neoadjuvant Therapy in Breast Cancer Patients

Led by Jiuda Zhao · Updated on 2025-01-17

140

Participants Needed

2

Research Sites

12 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the impact of supplemental vitamin D on the effectiveness and side effects of neoadjuvant therapy in patients with breast cancer. This randomized controlled Phase III trial aims to compare outcomes such as response rates and adverse effects between patients receiving standard therapy with or without added vitamin D. The study focuses on patients whose breast cancer is confirmed and who have low vitamin D levels before starting treatment. Participants are randomly assigned to one of two groups. One group receives standard neoadjuvant therapy plus vitamin D2 injections of 10 mg every three weeks throughout their treatment cycles. The other group receives only the standard neoadjuvant therapy, with dosages adjusted by their physician as needed. Both groups undergo treatment cycles approximately every three weeks until completion. Throughout the study, blood samples and imaging are collected before treatment and after every two therapy cycles to assess response. Researchers measure key outcomes including the objective response rate, pathological complete response rate, disease control rate, and significant adverse effects related to therapy. Side effects are monitored from treatment start until 21 days after the last therapy cycle. The total study duration for each participant spans about 4 to 6 months, allowing thorough evaluation of treatment impact and safety.

CONDITIONS

Brief Title

Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 80 years with ECOG performance status of 0-2
  • Primary diagnosis of breast cancer confirmed by preoperative pathology
  • Serum 25(OH)D levels less than 20 ng/ml (50 nmol/L)
  • No prior chemotherapy and planning at least 4 cycles of neoadjuvant chemotherapy or combined targeted therapy
  • Life expectancy of at least 6 months
  • No uncontrolled benign diseases at recruitment
  • Complete clinical medical records
  • Willing to voluntarily sign informed consent
Not Eligible

You will not qualify if you...

  • History of invasive breast cancer
  • Prior systemic treatment for breast cancer
  • Known allergies to vitamin D or calcium compounds
  • Comorbidities affecting vitamin D or calcium balance or bone health
  • Vitamin D or calcium supplementation within past 3 months
  • Presence of other tumors
  • Pregnant or lactating women
  • Individuals unwilling to participate

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 4 to 6 months

Participants receive standard neoadjuvant therapy with or without vitamin D2 supplementation every 3 weeks during each cycle of therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.

Visits every 3 weeks corresponding with each treatment cycle

Follow-up

Duration - Up to 3 weeks after last treatment cycle

Participants are monitored for side effects related to neoadjuvant therapy from the start of treatment up to 21 days after the last cycle.

Approximately 1 follow-up visit after treatment completion

Trial Site Locations

Total: 2 locations

1

Qinghai University Affiliated Hospital

Xining, Qinghai, China, 810000

Not Yet Recruiting

2

Qinghai University Affiliated Hospital

Xining, Qinghai, China, 810000

Actively Recruiting

Loading map...

Research Team

J

Jiuda Zhao

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Investigating The Role of Key Non-coding RNA(s) in Breast Ca...

Breast Cancer

Actively Recruiting

1 location

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Bre...

Breast Cancer

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here